Tukysa (tucatinib) [product monograph]. HC.

Regulatory approval published by the Health Canada.

Citation

Seagen Inc. Tukysa (tucatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00062119.PDF. Revised July 2021. Accessed June 2025.

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
TUKYSA (tucatinib) is indicated in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received prior treatment with trastuzumab, pertuzumab, and trastuzumab emtansine, separately or in combination.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Organizations	Biomarkers	Cancer types	Therapies